Summary of What CannaPharmaRx, Inc. Does

Business Focus

• Industry: Cannabis cultivation and production
• Primary Operations: Acquisition, development, and operation of cannabis cultivation facilities in Canada
• Core Business: Produces high-quality medical cannabis and craft cannabis products

Facilities

• Main Facility: A 55,000-square-foot indoor cannabis farm located in Cremona, Alberta, Canada
• Lease Term: 20-year operating lease entered into on January 6, 2022, expiring in 2042
• Facility Status: Recommissioned in 2022 with 11 growing rooms and one drying/packing room
• Current Operation: Operating 5 of 11 growing rooms and 1 drying/packing room
• Expansion Plans: Increase capacity to all 11 growing rooms and build an additional drying/packing room over 1-2 years

Licenses and Regulatory Approval

• Health Canada License: Received December 9, 2022
• CRA Cannabis License: Received December 22, 2022
• Production: Commenced cannabis production in 2023
• Products: Dried cannabis flowers, packaged for medicinal purposes, including trim shake
• Regulatory Environment: Operates under Canadian Cannabis Act, which legalized recreational and medical cannabis in 2018, with ongoing updates and guidelines

Growth Strategy

• Expansion of Production Capacity: From 5 to 11 growing rooms in the next 1-2 years
• Market Goals: Sell cannabis in European markets, especially focusing on Germany and Israel
• Certification Goals: Obtain EU-GMP certification to enable direct shipping within the EU, reducing costs and delivery times
• Sales Network Development: Building relationships and developing sales channels in Germany and Israel
• European E-Commerce: Accessing and developing online sales channels through a partnership and subsequent agreement with LTB Management, LLC

Business Operations and Revenue

• Products: Primarily dried cannabis flower for medicinal use
• Revenue for 2024: $820,137 (first year of revenue generation)
• Previous Year (2023): No revenue reported
• Cost of Goods Sold (2024): $3,755,064
• Profitability: The company reported a net loss of approximately $9.9 million in 2024
• Gross Margin: Negative gross loss of approximately $2.9 million in 2024 due to production costs and pricing below market levels

Employees and Workforce

• Number of Employees: 26 full-time employees
• Casual Staff: Fluctuating, depending on operational needs
• Management and Key Personnel: Includes a Master Grower and Quality Assurance personnel
• Union Status: No employees are part of a union
• Authorizations: Holds licenses for cultivation, processing, and sale of cannabis

Revenue and Customer Base

• Customer Base: Not explicitly stated; products sold for medical purposes in Canada and potentially for export to European markets
• Revenue: First year of reported revenue (2024), $820,137

Additional Details

• Market Position: Faces significant competition from larger companies with greater resources; market is described as "very saturated"
• Business Risks: Dependence on licenses, regulatory compliance, expanding production capacity, market acceptance, and international certification (EU-GMP)
• Financial Status:
  • Working Capital (as of Dec 2024): Negative with a deficiency of approximately $24.7 million
  • Cash on Hand (Dec 2024): $2,156
  • Net Income (2024): Loss of about $9.9 million

Summary

CannaPharmaRx, Inc. is a Canadian cannabis cultivator focusing on medical cannabis production at a large indoor facility in Alberta. It aims to expand capacity, develop export markets in Europe, and obtain necessary certifications to streamline distribution. The company has only recently begun generating revenue and reports a significant net loss, with limited cash reserves and ongoing reliance on raising capital. It faces intense competition within a saturated market and operates under a complex regulatory environment governing cannabis in Canada and internationally.